CN101160121B - 治疗癌症的组合物 - Google Patents

治疗癌症的组合物 Download PDF

Info

Publication number
CN101160121B
CN101160121B CN2006800127326A CN200680012732A CN101160121B CN 101160121 B CN101160121 B CN 101160121B CN 2006800127326 A CN2006800127326 A CN 2006800127326A CN 200680012732 A CN200680012732 A CN 200680012732A CN 101160121 B CN101160121 B CN 101160121B
Authority
CN
China
Prior art keywords
ebselen
allopurinol
cisplatin
cell
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800127326A
Other languages
English (en)
Chinese (zh)
Other versions
CN101160121A (zh
Inventor
J·奇尔
E·D·林奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sound Pharmaceuticals Inc
Original Assignee
Sound Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sound Pharmaceuticals Inc filed Critical Sound Pharmaceuticals Inc
Publication of CN101160121A publication Critical patent/CN101160121A/zh
Application granted granted Critical
Publication of CN101160121B publication Critical patent/CN101160121B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2006800127326A 2005-03-08 2006-03-08 治疗癌症的组合物 Expired - Fee Related CN101160121B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66142905P 2005-03-08 2005-03-08
US60/661,429 2005-03-08
PCT/US2006/008201 WO2006096759A2 (en) 2005-03-08 2006-03-08 Methods and compositions for treating cancer

Publications (2)

Publication Number Publication Date
CN101160121A CN101160121A (zh) 2008-04-09
CN101160121B true CN101160121B (zh) 2012-05-23

Family

ID=36954000

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800127326A Expired - Fee Related CN101160121B (zh) 2005-03-08 2006-03-08 治疗癌症的组合物

Country Status (8)

Country Link
US (2) US20060211745A1 (https=)
EP (1) EP1855662A4 (https=)
JP (1) JP2008533021A (https=)
KR (1) KR20070113262A (https=)
CN (1) CN101160121B (https=)
AU (1) AU2006220626A1 (https=)
CA (1) CA2600134A1 (https=)
WO (1) WO2006096759A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100628A2 (en) * 2007-02-16 2008-08-21 Synvista Therapeutics, Inc. Glutathione peroxidase mimetics for treatment of neurodegenerative, pulmonary and inflammatory diseases
US20080207679A1 (en) * 2007-02-16 2008-08-28 Noah Berkowitz Glutathione peroxidase mimetics for the treatment of dermatoses
GB0916010D0 (en) * 2009-09-11 2009-10-28 Isis Innovation JMJD2 demethylase inhibitors
GB201102248D0 (en) 2011-02-09 2011-03-23 Isis Innovation Treatment of bipolar disorder
US9085598B2 (en) 2011-10-28 2015-07-21 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds targeting the cell invasion protein complex, their pharmaceutical compositions and methods of use thereof
WO2014144850A1 (en) * 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2015200358A1 (en) 2014-06-24 2015-12-30 The Board Of Trustees Of The Leland Stanford Junior University Use of small molecules for the treatment of clostridium difficile toxicity
GB2550110A (en) * 2016-04-28 2017-11-15 Univ Oxford Innovation Ltd Treatment of impulsivity-related disorders
CN107714650A (zh) * 2016-08-11 2018-02-23 杭州健昵福生物科技有限公司 一种含谷氨酰胺代谢抑制剂脂质体及其药物组合物与用途
GB201717629D0 (en) 2017-10-26 2017-12-13 Univ Oxford Innovation Ltd Treatment of unipolar depressive disorder
US20210267984A1 (en) * 2018-09-03 2021-09-02 Wei Zhu Application of allopurinol in preparation of drug for treating cancer with high expression of paics gene
IT202200018339A1 (it) * 2022-09-08 2024-03-08 Univ Degli Studi Di Trento Composti del selenio e dello zolfo quali inibitori del riconoscimento degli RNA modificati da N6-metiladenosina da parte delle proteine YTHDF

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
WO2003045334A2 (en) * 2001-11-29 2003-06-05 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3027073C2 (de) * 1980-07-17 1985-03-07 A. Nattermann & Cie GmbH, 5000 Köln Pharmazeutische Präparate, enthaltend 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
DE3670635D1 (de) * 1985-04-27 1990-05-31 Nattermann A & Cie Neue benzisoselenazolonyl-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
DE3638124C2 (de) * 1986-11-08 1996-09-05 Nattermann A & Cie Neue pharmazeutische Verwendung von Ebselen
DE4024885C2 (de) * 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6177434B1 (en) * 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
EP1463507A1 (en) * 2001-12-19 2004-10-06 SmithKline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
ES2497716T3 (es) * 2002-01-04 2014-09-23 Sound Pharmaceuticals Incorporated Composiciones para utilizar en métodos destinados a tratar la pérdida auditiva
US6702850B1 (en) * 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
JP4532408B2 (ja) * 2003-03-13 2010-08-25 田辺三菱製薬株式会社 腫瘍形成抑制剤
US20050147978A1 (en) * 2003-12-30 2005-07-07 Jose Remacle Method for quantitative determination of multi-drug resistance in tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385726A (en) * 1990-08-06 1995-01-31 Rhone-Poulenc Rorer Gmbh Use of 2-phenyl-1,2-benzisoselenazol-3-(2H)-one
WO2003045334A2 (en) * 2001-11-29 2003-06-05 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy

Also Published As

Publication number Publication date
US20110020470A1 (en) 2011-01-27
AU2006220626A1 (en) 2006-09-14
KR20070113262A (ko) 2007-11-28
WO2006096759A2 (en) 2006-09-14
EP1855662A4 (en) 2009-12-23
CA2600134A1 (en) 2006-09-14
EP1855662A2 (en) 2007-11-21
WO2006096759A3 (en) 2007-04-05
US20060211745A1 (en) 2006-09-21
CN101160121A (zh) 2008-04-09
JP2008533021A (ja) 2008-08-21

Similar Documents

Publication Publication Date Title
US20110020470A1 (en) Methods and compositions for treating cancer
Nag et al. Auranofin protects intestine against radiation injury by modulating p53/p21 pathway and radiosensitizes human colon tumor
Yang et al. Clinical development of novel proteasome inhibitors for cancer treatment
US20220110940A1 (en) Combinations for the treatment of neoplasms using quiescent cell targeting with egfr inhibitors
Tao et al. Cellular hypoxia mitigation by dandelion-like nanoparticles for synergistic photodynamic therapy of oral squamous cell carcinoma
Indumathy et al. Finding chemo: The search for marine-based pharmaceutical drugs active against cancer
KR20030048127A (ko) 효과적인 항종양 치료
CA2466869C (en) Methods and compositions for ameliorating the undesirable effects of chemotherapy
KR20140143166A (ko) 조합 요법에 의한 프로카스파제 ３ 활성화
Pundir et al. VR23: A Quinoline–Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E–Mediated Centrosome Amplification
CN117065033A (zh) 一种治疗三阴乳腺癌的联合用药物
Sen et al. Differential sensitivities of triple‐negative breast cancer stem cell towards various doses of vitamin C: An insight into the internal antioxidant systems
KR101454866B1 (ko) 항암 약물로에 대한 무반응성 종양의 치료 및 화학증감을 위한 ｃｋ2 저해제의 용도
Doz et al. Phase I dose‐escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors
EP3128842B1 (en) Treatment of brca1-defective cancer or resistant cancers
He et al. Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats
Li et al. Autophagy in oral cancer: Promises and challenges
Ji et al. Synergistic effect of honokiol and 5‐fluorouracil on apoptosis of oral squamous cell carcinoma cells
Zhang et al. Anti‐cancer potential of selenium‐chitosan‐polyethylene glycol‐carvacrol nanocomposites in multiple myeloma U266 cells
Gervaso et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma
EP0877614B1 (en) Method for inducing death of neoplastic cells using piperazine oxirane derivatives
Schenkein Preclinical data with bortezomib in lung cancer
Borovskaya et al. Evaluation of the Effect of p-Tyrosol on the Level of DNA Damage in the DNA Comet Assay In Vivo
Zheng et al. Autophagy inhibition sensitizes LY3023414-induced anti-glioma cell activity in vitro and in vivo
Matos et al. Targets, structures, and recent approaches in malignant melanoma chemotherapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120523